ABCL News and Press, AbCellera Biologics Inc. From 08/13/21

Image source: The Motley Fool. AbCellera Biologics Inc. (NASDAQ: ABCL) Q2 2021 Earnings Call Aug 12, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: AbCellera Biologics Inc. (ABCL) Q2 2021 Earnings Call Transcript ...

AbCellera Biologics Inc. (ABCL) Q2 2021 Earnings Conference Call August 12, 2021, 05:00 PM ET Company Participants Tryn Stimart - Chief Legal Officer & Chief Compliance Officer Carl Hansen - CEO & President Andrew Booth - CFO Conference Call Participants Tiago Fauth - Credit Suisse Ga...

Total revenue of $28 million, up from $11 million in Q2 2020 Total programs under contract of 138, up 82% from Q2 2020 Net loss of ($0.01) per share (basic and diluted) compared to net earnings of $0.03 per share (basic and diluted) in Q2 2020 AbCe...

First, AbCellera is a Life Sciences Tools and Services play, not a biotech or pharmaceutical. By enabling pharmaceuticals and biotechs to rapidly develop cures, its platform fills a vital gap between innovative ideas and their fast execution. One of these cures targets the coronav...

AbCellera (NASDAQ:ABCL) perks up 3.4% premarket after announcing collaboration agreement with EQRx for the discovery and development of therapeutic antibodies. The collaboration will leverage AbCellera’s AI-powered antibody discovery technology to search and analyze natural i...

Collaboration leverages AbCellera’s AI-powered technology platform to identify novel antibody drug candidates for multiple disease targets across several therapeutic areas coupled with EQRx’s innovative model to accelerate the delivery and patient access to novel medicin...

AbCellera (NASDAQ:ABCL) and Tachyon Therapeutics announce a collaboration to facilitate the discovery and development of a therapeutic antibody targeting LEFTY1 in advanced cancers. Under the terms of the agreement, AbCellera is eligible to receive milestone payments and royalties on products...

LEFTY1, a secreted dual inhibitor of the NODAL/SMAD2 and BMP7/SMAD5 pathway, is implicated in driving cancer stem cell biology and unregulated tumor cell growth Tachyon Therapeutics, Inc. (Tachyon), a research and development focused biotechnology company, and AbCellera (Nas...

AbCellera (Nasdaq: ABCL) will announce its second quarter 2021 financial results on Thursday, August 12, 2021 and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. The live webcast of the earnings conference call will be available thro...

AbCellera (ABCL) announces that Neil Berkley has been appointed as the company's chief business officer ((CBO)).Berkley has more than 20 years of strategic planning and corporate and business development experience across a wide range of transactions and therapeutic indica...